Introduction
An increasing number of diseases are associated with the expression of proteins that misfold and interfere with diverse cellular processes. This is exemplified by neurodegenerative disorders including Parkinson's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and polyglutamine (polyQ) diseases. These diseases are associated with the chronic expression of specific disease-associated proteins resulting in the accumulation of misfolded species in brain tissues of individuals diagnosed with neurodegeneration (Soto and Estrada, 2008) . Despite the functional and structural diversity of proteins involved in these diseases, they all share common characteristics with the appearance of cytoplasmic, nuclear, or extracellular aggregates, inclusions, and amyloid-like material that has led to the protein misfolding hypothesis as a mechanism that leads to disease (Balch et al., 2008; Bucciantini et al., 2002) .
To protect itself from the stress of misfolded proteins, all cells express cytoprotective machinery that includes molecular chaperones, a family of highly conserved proteins that recognize nascent polypeptides and folding intermediates to guide proteins to their native state. Molecular chaperones are also involved in the assembly and disassembly of multimeric complexes, translocation of proteins across cellular membranes, and regulating vesicular transport (Bukau and Horwich, 1998; Hartl, 1996; Hartl and Hayer-Hartl, 2002) . Consequently, the genes that control these processes function as an integrated proteostasis network to maintain balance in protein biogenesis and to detect and prevent an imbalance leading to pathology and disease. Changes in the regulation of the proteostasis network or interference of chaperone function and clearance machineries are likely to have deleterious consequences in diseases 
